This clinical trial is focused on studying atopic dermatitis, a common skin condition that causes red, itchy, and inflamed skin. The study is testing a treatment called dupilumab, which is a medication given by injection. Dupilumab is already used to treat atopic dermatitis, and this trial aims to see if changing the frequency of injections can maintain the condition’s remission, meaning keeping the symptoms under control, in both adults and adolescents.
The purpose of the study is to compare a new approach of giving dupilumab injections less frequently with the current method of regular injections. Participants in the study will either continue with their regular dupilumab treatment or switch to the new approach. The study will last for one year, during which the participants’ skin condition will be monitored to see if the new approach is as effective as the regular treatment in controlling the severity of atopic dermatitis.
Throughout the study, participants will receive either the regular dupilumab treatment or the new step-down strategy, which involves spacing out the injections. The study will help determine if the new strategy can effectively maintain the remission of atopic dermatitis symptoms over the long term. Participants will be closely monitored to ensure their safety and to assess the effectiveness of the treatment strategies.
France 
